Skip to main content
Premium Trial:

Request an Annual Quote

ZymoGenetics Collects $120M in First Biotech IPO of 2002

NEW YORK, Feb. 1 - ZymoGenetics has earned $120 million in an IPO that also marks the first initial public offering for a biotech company this year, the company said on Friday. 


Shares in ZymoGenetics now trade on the Nasdaq exchange.

The company, a Seattle-based spinoff of Novo Nordisk, offered 10 million shares of its common stock at $12 apiece. They were trading at $12.01 just before noon on Friday.

The lead underwriters were Lehman Brothers and Merrill Lynch & Co. Co-lead managers were Bear, Stearns & Co. and Pacific Growth Equities.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.